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A B S T R A C T   
DJ-1 is a multifaceted protein with pleiotropic functions that has been implicated in multiple diseases, ranging 
from neurodegeneration to cancer and ischemia-reperfusion injury. Ischemia is a complex pathological state 
arising when tissues and organs do not receive adequate levels of oxygen and nutrients. When the blood flow is 
restored, significant damage occurs over and above that of ischemia alone and is termed ischemia-reperfusion 
injury. Despite great efforts in the scientific community to ameliorate this pathology, its complex nature has 
rendered it challenging to obtain satisfactory treatments that translate to the clinic. In this review, we will 
describe the recent findings on the participation of the protein DJ-1 in the pathophysiology of ischemia- 
reperfusion injury, firstly introducing the features and functions of DJ-1 and, successively highlighting the 
therapeutic potential of the protein.   
1. DJ-1: A multifunctional protein against cellular stress 
DJ-1 is a 189 amino-acid protein and exists as a homodimer of 20 
kDa highly conserved across phyla [1]. Alterations in the protein func-
tionality have been associated with different human diseases, ranging 
from Parkinson’s disease, cancer, male infertility, diabetes, stroke, 
chronic obstructive pulmonary disease, and ischemia-reperfusion (IR) 
injury [2,3]. The role of DJ-1 in several diseases reflects its wide pattern 
of expression, being found in most body tissues [4]. At the subcellular 
level, DJ-1 is localized primarily in the cytoplasm, though it has also 
been found to translocate to the nucleus and mitochondria, in particular, 
under conditions of stress [5–8]. In addition, DJ-1 has been shown to be 
secreted into the extracellular space in several pathologies, as it has been 
detected in the plasma or serum of patients affected by melanoma, 
breast cancer, and stroke [9–11]. 
Despite the great efforts in the scientific community, the physiolog-
ical function of DJ-1 is only partially understood. To date, several roles 
have been ascribed to the protein, including tumorigenesis, modulation 
of signaling cascades, preservation of ROS homeostasis, regulation of 
transcription, maintenance of glucose levels, and protection against 
protein aggregation [12,13]. Nonetheless, the most widely accepted 
function of DJ-1 is its protective role against excessive ROS levels [12, 
13]. In this regard, it has been suggested that DJ-1 may sense the cellular 
redox state through a highly conserved cysteine (Cys) residue, localized 
at position 106 [14]. Indeed, due to its low thiol pKa value, this residue 
exists almost exclusively as a reactive thiolate anion at physiological pH 
and it has been reported to be particularly sensitive to oxidation, 
probably regulating several functions attributed to the protein [15]. In 
the antioxidant defense, DJ-1 has been reported to orchestrate a large 
variety of responses to promote cell survival. In this frame, it has been 
shown that DJ-1 can indirectly affect transcription by interacting with 
transcription factors and their regulators, thus modulating gene 
expression [16]. In particular, the protein often leads to the activation of 
pro-survival and proliferative pathways, such as the extracellular 
signal-regulated protein kinases 1 and 2 (ERK1/2) [17], the nuclear 
factor erythroid 2-related factor 2 (Nrf2) [18], and the Akt pathways 
[19,20], while simultaneously dampening cell death signaling cascades, 
as reported for the pro-apoptotic transcription factor p53 [21,22] and 
the apoptosis signal-regulating kinase 1 (ASK1) [23–25]. In addition to 
the modulation of signaling cascades, different studies have reported the 
participation of DJ-1 in the maintenance of mitochondrial homeostasis. 
Indeed, DJ-1 has been described to interact with complex I [26,27] and, 
more recently, with the β subunit of F1FO ATP synthase [28], modulating 
their functionality. Moreover, the protein has been found to take part in 
the process of mitochondrial quality control, playing a role in the 
Parkin/PINK1-mediated mitophagy [29–32], and in the regulation of 
the mitochondrial dynamics [33–36]. Noteworthy, the protein has also 
been suggested to modulate endoplasmic reticulum-mitochondria 
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tethering, playing a role in the modulation of calcium transients [37,38]. 
Besides these largely explored functions, more recent findings have 
suggested that DJ-1 may also exert cellular protection by mitigating 
dicarbonyl stress. In particular, two glucose-derived metabolites, the 
methylglyoxal (MGO) and glyoxal (GO), are highly reactive, being able 
to attack and modify nucleophilic macromolecules, such as proteins and 
DNA, eventually yielding irreversible advanced glycation end products 
(AGEs) [39]. In this scenario, DJ-1 has been described to convert MGO 
and GO in less harmful species, by acting as a glutathione-independent 
glyoxalase [40–44]. Furthermore, some studies have reported that DJ-1 
can deglycate both proteins and nucleic acids upon reaction with MGO 
[45–50], though this function has proved contentious by other reports 
[51,52]. Interestingly, DJ-1 also seems to participate in the preservation 
of glucose homeostasis, by regulating the glucose levels in the brown 
adipose tissue [53] and by modulating the subcellular localization of the 
glycolytic enzyme hexokinase I [32]. Moreover, reduced expression 
levels of DJ-1 have been observed in the pancreatic islets of patients 
affected by type II diabetes, in contrast to healthy individuals, further 
supporting the role of the protein in glucose homeostasis [54]. 
The functions so far described clearly emphasize the protective po-
tential of DJ-1, which appears to play a multifaceted role in orches-
trating a wide range of responses to confer cellular protection. 
Interestingly, through the functions previously described, the protein 
has also recurrently been involved in the defense against IR injury, a 
condition that has been correlated with high levels of oxidative stress 
and underlies several pathologies, ranging from stroke to cancer and 
diabetes. The pathophysiology of IR injury will be discussed in detail in 
the following paragraphs, together with the recent studies that have 
highlighted the participation of DJ-1 in this condition. 
2. Pathophysiology of IR injury 
Ischemia results from an inadequate blood supply to tissues and or-
gans, commonly due to the obstruction of arterial flow [55]. As a 
consequence, the body experiences a local shortage of oxygen and nu-
trients until the blood flow is restored. This condition has relevance not 
only to stroke, myocardial infarction, and cancer [56] but also to dia-
betes [57,58], and neurodegenerative pathologies [59–61]. At the 
molecular level, one of the key events occurring in response to hypoxia is 
the activation of the transcription factor Hypoxia Inducible Factor 1α 
(HIF-1α), which otherwise, under normal oxygen tension, is constantly 
degraded [62]. The oxygen-dependent regulation of HIF-1α is deter-
mined by the E3 ubiquitin ligase Von Hippel-Lindau (VHL), which labels 
HIF-1α for proteasomal degradation. The interaction with VHL is 
dependent on HIF-1α hydroxylation by the prolyl hydroxylase domain 
(PHD) protein, which uses oxygen and α-ketoglutarate as substrates 
[62]. Under limited oxygen availability, HIF-1α is stabilized and or-
chestrates the expression of multiple genes involved in the hypoxic 
adaptation, including those participating in vascularization and 
reprogramming of energy metabolism [63]. Indeed, while under nor-
moxia, ATP synthesis largely relies on oxidative phosphorylation, hyp-
oxic ATP production is driven by glycolysis [55]. Nonetheless, the 
cellular energetic demand exceeds the glycolytic capacity, eventually 
leading to a drop in ATP levels. Since ATP is required as a regulator of 
different ATP-dependent ionic exchangers, the hypoxic period leads to 
ionic imbalance and cellular acidosis due to the accumulation of lactate 
[55]. In particular, due to the altered function of Na+/Ca2+ and Na+/H+
exchangers, and of Na+/K+-ATPase, ischemia drives the intracellular 
accumulation of sodium and calcium, affecting the entire cellular ho-
meostasis (see Fig. 1) [55,64]. Notably, this ionic imbalance becomes 
even more severe upon reperfusion, when the mitochondrial respiration 
resumes, and the physiological pH begins to be restored. Indeed, while 
the extracellular pH is more rapidly normalized with respect to the 
cytosol, the intracellular compartment remains still partially acidic upon 
reoxygenation. This condition entails a proton gradient able to sustain 
the function of the Na+/H+ and Na+/Ca2+ exchangers, further 
increasing the cytosolic levels of sodium and calcium [65]. 
In addition to this ionic dyshomeostasis, the first minutes of reper-
fusion are characterized by an abundant ROS generation, principally of 
mitochondrial origin. When the oxygen concentration is reduced, the 
levels of the mitochondrial metabolite succinate dramatically rise. 
Succinate is thought to arise due to the reversal activity of complex II, 
converting fumarate to succinate, though there may also be a contri-
bution from the canonical Krebs cycle supported by glutaminolysis 
[66–68]. During hypoxia, succinate plays a role in HIF1-α stabilization 
as it is also transported to the cytosol, where it can inhibit PHDs [69,70]. 
However, upon reoxygenation, succinate is oxidized back to fumarate by 
complex II and this event forces electrons to flow from the co-enzyme Q 
pool back through complex I and onto oxygen through the process 
referred to as reverse electron transfer (RET), producing large amounts 
of superoxide anions [66,71]. This initial burst of ROS in conjunction 
with the conspicuous surge of calcium act as major players in the acti-
vation of cell death signaling cascades, which involve the opening of the 
mitochondrial permeability transition pore (mPTP) [72]. mPTP is 
considered a high conductance proteinaceous pore localized in the inner 
mitochondrial membrane [73]. After ischemia, the mPTP opening is 
stimulated within a few minutes of reperfusion, when the pH is 
normalized to pre-ischemic values. Indeed, it has been shown that mPTP 
opening is almost inhibited by pH values below 7.0, probably due to a 
highly conserved histidyl residue of the mitochondrial F1FO (F)-ATP 
synthase complex [74]. Once opened, mPTP increases the permeability 
of the inner mitochondrial membrane leading to mitochondrial swelling 
and subsequent activation of cell death pathways [72]. 
Following the acute phase of reperfusion injury, the release of 
damage-associated molecular patterns (DAMPs) from injured cells leads 
to activation of an innate immune response [71,75]. Interestingly, me-
tabolites, such as lactate and succinate, effluxed into the circulation 
during reperfusion, have also recently been postulated to play a role in 
this immune activation [76,77]. The initial immune response induces 
the production of pro-inflammatory cytokines and chemokines, facili-
tating the infiltration of leukocytes and an inflammatory response [78]. 
As a consequence, the production of pro-inflammatory cytokines and 
chemokines facilitate the infiltration of leukocytes and an inflammatory 
response, which can further exacerbate the extent of tissue damage. 
Fig. 1. Events contributing to the pathophysiology of IR injury. - (A) Under limited 
oxygen concentrations, the mitochondrial respiration is inhibited with conse-
quent upregulation of glycolysis and acidosis. To counterbalance the low pH, 
Na+/H+ exchanger (NHE) exchanges protons for Na+, promoting the build-up 
of the ion in the cytosol. As Na+/K+ ATPase (NAK) activity is almost inhibi-
ted due to the reduced ATP availability, cells exploit the reverse activity of the 
Na+/Ca+ exchanger (NCX) to counterbalance the increased sodium level. In this 
way, NCX induces Ca2+ accumulation in the cytosol, while expelling sodium. At 
the same time, the transcription factor HIF1-α is stabilized and enters the nu-
cleus to promote gene expression. (B) Upon reperfusion, the mitochondrial 
respiration resumes, re-establishing the normal pH. This rapid pH adjustment 
causes a large proton gradient that prompts a sustained NHE activity, which 
additionally rises the cytosolic concentration of sodium. As a consequence, the 
NCX reverse activity is potentiated, further incrementing the calcium level in 
the intracellular compartment. In this condition, calcium, in conjunction with 
the large mitochondrial ROS production, favours the opening of the mPTP, 
which stimulates the initiation of cell death mechanisms. In this condition, 
HIF1-α is constantly degraded. 
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2.1. Therapeutic approach 
Ischemic injury represents a debilitating pathology and is often 
regarded as a medical emergency, characterized by its high incidence 
and a complex clinical picture. Depending on the origin of the ischemic 
event, the treatment can vary but it commonly comprises the rapid 
administration of anti-thrombotic, anti-coagulative, and vasodilatory 
compounds, accompanied by surgical interventions, if necessary [79]. 
Nonetheless, the intricate etiology of IR injury has rendered it chal-
lenging to obtain efficacious therapies to treat the pathology. For this 
reason, the use of experimental models represents an essential approach 
to better comprehend this pathological condition and to investigate new 
therapeutic approaches. 
To study ischemia, both in vivo and in vitro models are usually 
generated by reducing oxygen concentrations or by limiting the utili-
zation of oxygen by organs/tissues. Many animal models rely on the 
occlusion of the target organ arteries, followed by the release of the 
suture to reperfuse the tissue [65,80]. Most in vivo studies have been 
performed in rodents, as their anatomy and physiology display a discrete 
similarity to humans. Besides in vivo models, researchers also take 
advantage of in vitro models, in which the selected cellular model is 
maintained in a hypoxic chamber for the designated experimental time. 
Moreover, cells can be cultured in a glucose-free acidified medium, 
which can be supplemented with lactate to mimic its accumulation as 
normally occurring during anaerobic glycolysis. Successively, reperfu-
sion is promoted by exposing cells to normal oxygen tension and 
replacing the culture medium with a pH-adjusted one, enriched in 
essential nutrients [65]. The utilization of experimental models has led 
to the development of promising therapeutic interventions, including 
both pharmacological and non-pharmacological treatments. In this re-
gard, hypoxic/ischemic conditioning has emerged as a possible mech-
anism to lessen the ischemic-associated damage [81]. Conditioning 
consists of the application of a series of sublethal hypoxic/ischemic 
cycles, which can be performed before the onset of the ischemic episode 
to reduce the infarct size (preconditioning) or upon reox-
ygenation/reperfusion to diminish the associated damage (post-
conditioning) [82–84]. In addition to pre/postconditioning, remote 
conditioning has also been reported to display protective effects through 
the application of brief hypoxic/ischemic episodes to an organ remote 
from the injured site [85,86]. However, the beneficial effects in human 
trials are less than clear, with some conflicting results on the protective 
effects [87]. Furthermore, hypothermia has also been observed to confer 
protection by lowering the metabolic rate and by delaying the activation 
of pro-inflammatory and pro-oxidant pathways [88–90]. Besides these 
non-pharmacological approaches, the explored treatments also include 
pharmacological strategies, which target molecular pathways known to 
be affected during hypoxia/ischemia. Thus, the investigated mecha-
nisms encompass the inhibition of Na+/H+ [91–93] and Na+/Ca2+ ex-
changers to modulate calcium levels [94–96], blockage of mPTP 
opening [97,98], reduction of cytokine and interleukin release [99,100], 
and counteracting ROS production [101–103]. Recently, it has become 
clear that mitochondrial ROS generation importantly contributes to the 
major damage observed upon hypoxic/ischemic manifestations. There-
fore, there is great interest in treatments able to protect against ROS 
generation, principally targeting mitochondria. In this frame, the 
reduction of mitochondrial respiration has been observed to reduce the 
pathology-associated damage [104]. For example, the inhibition of 
succinate accumulation or prevention of its rapid oxidation upon reox-
ygenation, by using drugs based on the mitochondrial complex II 
competitive inhibitor malonate, have proven to display beneficial results 
[66,101,105–107]. Similarly, blockade of complex I, for example with 
rotenone [108,109] or preventing complex I reactivation during reper-
fusion by S-nitrosylation of critical cysteines [110–113], have been 
demonstrated to ameliorate the detrimental response to reoxygenation. 
While on the one hand the aforementioned therapeutic approach is to 
reduce ROS generation, on the other hand there is a focus on 
upregulating the antioxidant capacity of the cell. The explored ap-
proaches include the use of superoxide dismutases and relative mimetics 
[103,114–116], the mitochondrially targeted antioxidant MitoQ [102, 
117,118], N-acetylcysteine [119,120], metformin [121,122], which also 
acts as a weak complex I inhibitor [123], and the administration of 
natural compounds, such as vitamin C [124]. In addition, recent studies 
have reported the cardioprotective potential of a mitochondrially tar-
geted MGO and GO scavenger, referred to as MitoGamide, which might 
be a future promising candidate for IR therapy [125,126]. Besides these 
compounds in the antioxidant field, interesting insights have been ob-
tained from studies involving the multifaceted protein DJ-1, which is 
gaining more and more attention as a protective player in response to IR 
injury. 
3. The involvement of DJ-1 in IR injury 
Compelling evidence has reported the participation of DJ-1 in the 
response to IR injury. The protein has been described to act on two 
levels: firstly, by sustaining the hypoxic response under oxygen deple-
tion, and then by protecting against reoxygenation-related damage. 
3.1. Participation in the ischemic response 
Under limited oxygen concentrations, DJ-1 has been reported to 
stabilize HIF1-α [127,128]. Vasseur and colleagues initially found that 
DJ-1 silencing in osteosarcoma-derived cells reduced HIF-1α levels by 
30% under hypoxic treatment [128]. Successively, working with 
neuronal cell models, Parsanejad and co-workers identified VHL as a 
DJ-1-interacting protein through immunoprecipitation, proposing that 
DJ-1 may act as a negative regulator of VHL, to boost HIF1-α and prevent 
its proteasomal degradation [127]. Furthermore, in accordance with 
other studies [129,130], the authors did not observe any significant 
reduction in HIF1-α mRNA levels upon DJ-1 deficiency, suggesting that 
DJ-1 does not influence HIF1-α gene expression [127]. Although the 
modulation of the VHL–HIF–1α interaction has been proposed as a 
possible mechanism of action of DJ-1 in neuronal cells, it may not be a 
general mechanism. Indeed, a more recent study, conducted in colo-
rectal cancer cells, has reported that DJ-1 may promote HIF-1α accu-
mulation through the PI3K/Akt pathway [130], supporting that diverse 
mechanisms could be activated in different tissues. Moreover, it is 
relevant to mention that another group has observed HIF-1α protein 
accumulation upon DJ-1 silencing in neuroblastoma cells [129], sug-
gesting instead, that DJ-1 could play a negative role in HIF1-α stabili-
zation. In an attempt to interpret these contrasting findings, it should be 
considered that different cell types may express different levels of 
endogenous DJ-1 and have different susceptibility to the hypoxic 
treatment. Moreover, the stabilization of HIF-1α is frequently detected 
via immunoblot, which may yield variable results, considering the labile 
nature of HIF-1α. Therefore, future analyses are required to clarify how 
DJ-1 is involved in the regulation of HIF1-α and target genes, and 
whether the contrasting data reported are due to the diverse experi-
mental model and approach used. 
Upon oxygen reintroduction, DJ-1 has been shown to protect against 
reoxygenation-derived ROS damage, acting at different levels. Indeed, in 
vivo studies have reported that the absence or down-regulation of DJ-1 
results in higher sensitivity to ischemia and increased infarct size in 
the brain [131–134] and heart [135,136]. On the contrary, DJ-1 upre-
gulation has been observed to elicit neuroprotection and car-
dioprotection, as its overexpression or injection was reported to rescue 
post-ischemic cerebral [131,132,137] and myocardial damage [138]. 
In addition, it is emerging that DJ-1 may play a role in ischemic pre-
conditioning. During in vivo preconditioning, DJ-1 expression levels 
have been shown to increase, whilst knock-down of the protein seemed 
to impair the beneficial effects of the treatment [139]. This protective 
effect has also been observed in cellular models of hypoxic pre-
conditioning, where DJ-1 protein was found to be upregulated [140, 
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141]. Furthermore, two additional studies have emphasized that DJ-1 
may play a role during ischemic postconditioning [142–144]. None-
theless, it is worth mentioning that confounding results have been ob-
tained concerning the modulation of DJ-1 expression levels upon IR. 
Indeed, while some studies have reported an increased DJ-1 expression 
[24,144–146], other groups have observed no change [142,147] or even 
a decreased expression level [148,149]. As these discrepancies may be 
attributable to different models, experimental procedures, or time 
windows considered, more studies should be performed to elucidate 
whether and how DJ-1 expression is transcriptionally regulated under 
this condition. Moreover, to precisely evaluate its participation in the 
reperfusion phase, DJ-1 levels should be modulated only during reox-
ygenation to avoid confounding results deriving from the combination 
of ischemia and reperfusion injury. 
3.1.1. Modulation of mitochondrial function 
Despite conflicting reports on its expression levels during ischemic 
events, the protective activity exerted by the protein is becoming more 
and more evident, even though the precise mechanisms of action remain 
to be completely elucidated. In this regard, different in vitro reports have 
found that the protein could act at the mitochondrial level. Accordingly, 
upon reperfusion, DJ-1 was observed to translocate into mitochondria of 
rat primary neural cells and isolated murine cardiomyocytes [136,150] 
and this process might be mediated by the mitochondrial chaperone 
glucose-regulated protein 75 (Grp75) [142,147]. Moreover, DJ-1 has 
been described to translocate within the mitochondrial compartment in 
the hypoxic phase, prior to the reoxygenation process. Indeed, a study 
reported that the mitochondrial accumulation of DJ-1 under hypoxia 
occurs in both HEK cells and rat primary cortical neurons and that the 
translocation may rely on 14-3-3 proteins [151]. In this compartment, 
the protein has been reported to reduce mitochondrial fragmentation 
and to sustain complex I activity in cardiac cells [135,136,140,152]. In 
addition, DJ-1 overexpression has been observed to contribute to a delay 
in mPTP opening in HL-1 cells subjected to simulated IR [135] and to 
participate in the protective mechanisms exerted by cyclosporine A, a 
drug that has been described to prevent mPTP opening [153], sup-
porting a role for DJ-1 in mPTP formation. Therefore, DJ-1 appears to 
regulate mitochondrial homeostasis through different mechanisms 
during both ischemia and reperfusion. 
3.1.2. Modulation of ion homeostasis 
Other interesting insights into the involvement of DJ-1 in IR injury 
have been obtained by a few studies that have highlighted the possible 
participation of the protein in the modulation of ionic currents. In this 
frame, a DJ-1-based peptide, named ND-13, has been selected from a 
library of other DJ-1-related peptides for its ability to exert protection 
against oxidative and toxic insults in vitro [154]. The peptide has been 
designed on a conserved portion of DJ-1 (KGAEEMETVIPVD) and 
attached to a 7 amino-acid region of the cell-penetrating peptide derived 
from the HIV trans-activator of transcription (TAT) protein (YGRKKRR) 
[154]. Interestingly, ND-13 has been reported to influence the expres-
sion of proteins involved in the activation of Ca2+− activated K+ channels 
and Kv4 voltage-gated channels, which have been associated with 
increased resistance to IR injury by reducing the cellular excitability and 
excitotoxicity, respectively [132]. Moreover, DJ-1 null dopaminergic 
neurons have been described to display greater hyperpolarization upon 
oxygen-glucose deprivation than control cells and that this alteration 
might derive from the participation of DJ-1 in the modulation of the 
activity of Na+/K+ ATPases, although the underlying mechanisms of 
action have not been investigated [155]. These studies suggest the 
possible participation of DJ-1 in the modulation of ion homeostasis 
during IR, though additional research is required to validate this 
activity. 
3.1.3. Regulation of signaling pathways 
Apart from the direct mitochondrial-related functions, other studies 
have shown that DJ-1 protection could derive from the activation of 
antioxidant signaling pathways. For example, DJ-1 was demonstrated to 
induce Nrf2-dependent gene expression, such as SOD2, catalase, and 
glutathione peroxidase, in rat heart cells [138,156]. In this regard, DJ-1 
has been reported to regulate Nrf2 activation also in reactive astro-
cytes, where the protein is abundantly expressed [133]. Interestingly, 
the same group has proposed that astrocytic DJ-1 could play an 
anti-inflammatory role by regulating the expression of inflammatory 
cytokines and through modulation of the interaction between TRAF6, a 
member of the TNF receptor-associated factor protein family, and 
NLRX1, a member of the NOD-like family with anti-inflammatory 
properties [157]. Additionally, DJ-1 has been described as a mediator 
of the protective effects from resveratrol against cardiac reoxygenation 
damage by indirectly driving the deacetylation of the pro-apoptotic 
transcription factor p53 [146]. Notably, DJ-1 cardioprotection has 
also been partially attributed to its ability to counteract glycation stress. 
Indeed, the loss of the protein has been found to favor AGEs accumu-
lation, with consequent activation of AGEs receptors in the murine heart 
upon IR [158]. In this line, the protein has also been suggested to 
intervene in the cardioprotection against IR injury in diabetic condi-
tions, possibly by upregulating the Akt cascade and autophagy in dia-
betic rats subjected to IR injury [143,159,160]. Moreover, the protein 
seems to elicit a similar protective role in the kidneys, where DJ-1 has 
been found to be upregulated after myocardial ischemia in diabetic rats, 
supposing a possible role in this organ [53]. In accordance, DJ-1 over-
expression has been reported to defend against oxidative stress in 
NRK-52E renal cells subjected to hypoxia and high glucose concentra-
tions [161]. Although the function of DJ-1 in the context of diabetic 
ischemia is still at the dawn, it could represent an interesting aspect to 
reflect on. As diabetic patients are considered more vulnerable to 
ischemic damage and present with an increased risk of morbidity [57, 
162], the ability of DJ-1 to protect against IR injury in hyperglycemic 
conditions should be further explored. 
Besides the ability to act at the cytosolic level, the protein has also 
been suggested to be protective in the extracellular compartment. 
Indeed, extracellularly applied DJ-1 has been shown to rescue neuro-
blastoma cells exposed to oxygen-glucose deprivation, although the 
precise mechanism remains elusive [163]. In this regard, the secreted 
form of the protein has been found in oxygen-glucose deprived human 
neural progenitor cells [150], supporting a role of the protein in the 
extracellular milieu. Even though the participation of DJ-1 in signaling 
cascades has been recurrently reported, the picture that emerges from 
these data renders it difficult to understand whether the pathways here 
reported represent general targets of DJ-1 activity or whether the pro-
tein exerts different functions in a tissue-specific manner. In this frame, 
it is worth mentioning that while the role of DJ-1 has been mostly 
examined at the brain level, due to its association with neuro-
degeneration, less is known about its function in the heart and kidneys 
or other organs. Therefore, further studies are awaited to examine the 
role of DJ-1 in these tissues and to clarify whether the protein displays 
shared or distinct mechanisms of action in different organs. 
4. Concluding remarks 
Although the protective activity of DJ-1 against IR injury is highly 
supported in the literature, as here discussed, further investigation is 
required to better comprehend the mechanisms underlying its protec-
tion. In this regard, it would be interesting to explore the signals 
responsible for the activation of the protein. Upon reperfusion, ROS may 
be responsible for the activation of DJ-1’s protective function, suggest-
ing the protein may be redox-sensitive. Therefore, it could be evaluated 
whether and how the highly conserved Cys-106 residue is involved. 
Indeed, so far, few studies have addressed this point, mainly reporting 
that this cysteine is important for DJ-1 to carry out its functions [131, 
135]. Of note, Ariga’s group has performed an in silico virtual screening 
to find DJ-1-binding compounds that are able to stabilize the reduced 
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and mildly oxidized state of this residue [164]. Interestingly, the results 
obtained with ‘compounds 23, A and B’ showed the beneficial effects of 
these molecules in rat models of cerebral ischemia, supporting the 
therapeutic potential of modulating DJ-1 redox-state [165–167]. 
Nonetheless, the DJ-1-based peptide, ND-13, which has been shown to 
improve focal ischemia recovery, does not contain this amino acid, 
suggesting that this residue may not be the only determinant for its 
function [132]. Therefore, further research is essential to untangle this 
aspect. Moreover, while ROS may favor DJ-1 activation upon reoxyge-
nation, under ischemic conditions, where ROS generation is largely 
repressed due to oxygen depletion, other signals might promote the 
participation of DJ-1 in HIF-1α stabilization. For example, HIF-1α can be 
stabilized upon succinate accumulation [69,70]. As DJ-1 has been 
associated with mitochondrial metabolism [168] and the ND-13 
DJ-1-based peptide can regulate succinate dehydrogenase assembly 
factor 4 protein levels [132], this other mechanism of HIF-1α stabili-
zation should be considered in order to better comprehend the partici-
pation of DJ-1 in HIF-1α regulation. 
In conclusion, the findings discussed here suggest that the multi-
faceted behavior of DJ-1 confers the ability to protect against IR injury 
by orchestrating a wide-spectrum of cellular responses and by acting in 
multiple tissues (Fig. 2). Although studies robustly validating previously 
discovered roles, and new studies dissecting the precise mechanisms of 
action of the protein in this pathological state are essential, DJ-1 may be 
considered an interesting candidate to investigate for future therapeutic 
implications in IR injury. 
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Nrf2 (nuclear factor erythroid 2-related factor 2) 
PHD (prolyl hydroxylase domain) 
PI3K (phosphoinositide 3-kinase) 
RET (reverse electron transport) 
ROS (reactive oxygen species) 
SOD (superoxide dismutase enzyme) 
TAT (trans-activator of transcription) 
TRAF6 (TNF receptor associated factor 6) 
VDAC (voltage-dependent anion channel 1) 
VHL (Von Hippel-Lindau) 
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unique histidine in OSCP subunit of F-ATP synthase mediates inhibition of the 
permeability transition pore by acidic pH, EMBO Rep. 19 (2018) 257–268, 
https://doi.org/10.15252/embr.201744705. 
[75] J. Lutz, K. Thurmel, U. Heemann, Anti-inflammatory treatment strategies for 
ischemia/reperfusion injury in transplantation, J. Inflamm. 7 (2010) 27, https:// 
doi.org/10.1186/1476-9255-7-27. 
[76] H.A. Prag, A.V. Gruszczyk, M.M. Huang, T.E. Beach, T. Young, L. Tronci, 
E. Nikitopoulou, J.F. Mulvey, R. Ascione, A. Hadjihambi, M.J. Shattock, 
L. Pellerin, K. Saeb-Parsy, C. Frezza, A.M. James, T. Krieg, M.P. Murphy, 
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